Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport

被引:100
作者
Song, Xueqin [1 ]
Lorenzi, Philip L. [1 ]
Landowski, Christopher P. [1 ]
Vig, Balvinder S. [1 ]
Hilfinger, John M. [2 ]
Amidon, Gordon L. [1 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] TSRL Inc, Ann Arbor, MI 48108 USA
关键词
peptide transporter; gemcitabine; amino acid esters; prodrug; cytidine deaminase;
D O I
10.1021/mp049888e
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3'-Monoester, 5'-monoester, and 3',5'-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (1C(50): 0.14-0.16 mM) for the transporter. However, only the 5'-L-valyl and 5'-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in HeLa/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5'-L-valyl and 5'-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.
引用
收藏
页码:157 / 167
页数:11
相关论文
共 38 条
[1]   Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir [J].
Balimane, PV ;
Tamai, I ;
Guo, AL ;
Nakanishi, T ;
Kitada, H ;
Leibach, FH ;
Tsuji, A ;
Sinko, PJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (02) :246-251
[2]   Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) [J].
Bergman, AM ;
Pinedo, HM ;
Peters, GJ .
DRUG RESISTANCE UPDATES, 2002, 5 (01) :19-33
[3]   KINETIC-STUDIES ON 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) WITH PURIFIED HUMAN DEOXYCYTIDINE KINASE AND CYTIDINE DEAMINASE [J].
BOUFFARD, DY ;
LALIBERTE, J ;
MOMPARLER, RL .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (09) :1857-1861
[4]   PURIFICATION AND PROPERTIES OF CYTIDINE DEAMINASE FROM NORMAL AND LEUKEMIC GRANULOCYTES [J].
CHABNER, BA ;
JOHNS, DG ;
COLEMAN, CN ;
DRAKE, JC ;
EVANS, WH .
JOURNAL OF CLINICAL INVESTIGATION, 1974, 53 (03) :922-931
[5]  
CHABNER BA, 2001, GOODMAN GILMANS PHAR, pCH52
[6]   A novel high-throughput PepT1 transporter assay differentiates between substrates and antagonists [J].
Faria, Teresa N. ;
Timoszyk, Julita K. ;
Stouch, Terry R. ;
Vig, Balvinder S. ;
Landowski, Christopher P. ;
Amidon, Gordon L. ;
Weaver, C. David ;
Wall, Doris A. ;
Smith, Ronald L. .
MOLECULAR PHARMACEUTICS, 2004, 1 (01) :67-76
[7]   Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs [J].
Fleisher, D ;
Bong, R ;
Stewart, BH .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (02) :115-130
[8]   Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells [J].
Friedrichsen, GM ;
Chen, WQ ;
Begtrup, M ;
Lee, CP ;
Smith, PL ;
Borchardt, RT .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 16 (1-2) :1-13
[9]  
Gonzalez DE, 1998, CANCER RES, V58, P519
[10]   Clinical, toxicological and pharmacological aspects of gemcitabine [J].
Guchelaar, HJ ;
Richel, DJ ;
vanKnapen, A .
CANCER TREATMENT REVIEWS, 1996, 22 (01) :15-31